These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 17303388)

  • 1. Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia.
    Wehmeier PM; Kluge M; Schacht A; Helsberg K; Schreiber W
    Schizophr Res; 2007 Mar; 91(1-3):178-86. PubMed ID: 17303388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.
    Wehmeier PM; Kluge M; Schneider E; Schacht A; Wagner T; Schreiber W
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):703-12. PubMed ID: 17289237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia.
    Wehmeier PM; Kluge M; Schacht A; Helsberg K; Schreiber W; Schimmelmann BG; Lambert M
    J Psychiatr Res; 2008 Jul; 42(8):676-83. PubMed ID: 17720192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia.
    Naber D; Riedel M; Klimke A; Vorbach EU; Lambert M; Kühn KU; Bender S; Bandelow B; Lemmer W; Moritz S; Dittmann RW
    Acta Psychiatr Scand; 2005 Feb; 111(2):106-15. PubMed ID: 15667429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subjective well-being in schizophrenia: a randomised controlled open-label 12-month non-inferiority study comparing quetiapine XR with risperidone (RECOVER).
    Naber D; Peuskens J; Schwarzmann N; Goltz M; Krüger H; Lambert M; Haro JM
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1257-69. PubMed ID: 23953270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gender differences in response to antipsychotic treatment in outpatients with schizophrenia.
    Usall J; Suarez D; Haro JM;
    Psychiatry Res; 2007 Dec; 153(3):225-31. PubMed ID: 17681611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia.
    Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Zhou W; Kapur S; Kane JM; Naber D
    Schizophr Res; 2010 May; 118(1-3):176-82. PubMed ID: 20080036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study.
    Haro JM; Edgell ET; Novick D; Alonso J; Kennedy L; Jones PB; Ratcliffe M; Breier A;
    Acta Psychiatr Scand; 2005 Mar; 111(3):220-31. PubMed ID: 15701107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
    Tollefson GD; Andersen SW
    J Clin Psychiatry; 1999; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting a 'combined treatment outcome' in chronic schizophrenia: the role of demographics, symptomatology, functioning and subjective well-being.
    Naber D; Kollack-Walker S; Chen J; Stauffer VL; Kinon BJ; Case M; Ascher-Svanum H; Kapur S; Kane JM
    Pharmacopsychiatry; 2013 May; 46(3):114-9. PubMed ID: 23293013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of subjective and objective quality of life in outpatients with schizophrenia.
    Yamauchi K; Aki H; Tomotake M; Iga J; Numata S; Motoki I; Izaki Y; Tayoshi S; Kinouchi S; Sumitani S; Tayoshi S; Takikawa Y; Kaneda Y; Taniguchi T; Ishimoto Y; Ueno S; Ohmori T
    Psychiatry Clin Neurosci; 2008 Aug; 62(4):404-11. PubMed ID: 18778437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study.
    Alonso J; Croudace T; Brown J; Gasquet I; Knapp MR; Suárez D; Novick D
    Value Health; 2009 Jun; 12(4):536-43. PubMed ID: 19900255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic literature review identifying associations between outcomes and quality of life (QoL) or healthcare resource utilization (HCRU) in schizophrenia.
    Germain N; Kymes S; Löf E; Jakubowska A; François C; Weatherall J
    J Med Econ; 2019 May; 22(5):403-413. PubMed ID: 30696307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is it true remission? A study of remitted patients affected by schizophrenia and schizoaffective disorders.
    Pinna F; Deriu L; Lepori T; Maccioni R; Milia P; Sarritzu E; Tusconi M; Carpiniello B;
    Psychiatry Res; 2013 Dec; 210(3):739-44. PubMed ID: 24007858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Functional status and quality of life in Latin American outpatients with schizophrenia treated with atypical or typical antipsychotics: outcomes of the 12 months schizophrenia outpatient health outcomes (IC-SOHO) Study].
    Rovner J; Assunção S; Gargoloff P; Ibarra HS; Gasca JA; Fournais EL; Adan P; Andrades NJ; Dyachkova Y
    Vertex; 2005; 16(63):332-41. PubMed ID: 16220148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Validation of the Spanish version of the Subjective Well-being under Neuroleptic Scale (SWN-K) in patients with schizophrenia].
    Sanjúan J; Haro JM; Mauriño J; Díez T; Ballesteros J
    Med Clin (Barc); 2012 Feb; 138(4):151-4. PubMed ID: 21571347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: A 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizers.
    Ritsner MS; Gibel A
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1442-52. PubMed ID: 16842897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs.
    Naber D; Moritz S; Lambert M; Pajonk FG; Holzbach R; Mass R; Andresen B
    Schizophr Res; 2001 May; 50(1-2):79-88. PubMed ID: 11378316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables.
    Naber D
    Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():133-8. PubMed ID: 8866775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.